| # | Title | Journal | Year | Citations |
|---|
| 1 | Overview of the 8th Edition TNM Classification for Head and Neck Cancer | Current Treatment Options in Oncology | 2017 | 455 |
| 2 | Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer | Current Treatment Options in Oncology | 2015 | 309 |
| 3 | Metastatic renal cell carcinoma | Current Treatment Options in Oncology | 2003 | 248 |
| 4 | Parathyroid Carcinoma: Update and Guidelines for Management | Current Treatment Options in Oncology | 2012 | 246 |
| 5 | Targeted Therapies for Triple-Negative Breast Cancer | Current Treatment Options in Oncology | 2019 | 237 |
| 6 | Current State of Immunotherapy for Treatment of Glioblastoma | Current Treatment Options in Oncology | 2019 | 215 |
| 7 | Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis | Current Treatment Options in Oncology | 2008 | 207 |
| 8 | Current Treatment Options for Metastatic Head and Neck Cancer | Current Treatment Options in Oncology | 2012 | 197 |
| 9 | Multiple myeloma | Current Treatment Options in Oncology | 2000 | 190 |
| 10 | Treatment of Relapsed/Refractory Acute Myeloid Leukemia | Current Treatment Options in Oncology | 2017 | 179 |
| 11 | Cancer-Related Fatigue: Causes and Current Treatment Options | Current Treatment Options in Oncology | 2020 | 174 |
| 12 | The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment | Current Treatment Options in Oncology | 2017 | 165 |
| 13 | Treatment of metastatic malignant melanoma | Current Treatment Options in Oncology | 2005 | 156 |
| 14 | Post Transplant Lymphoproliferative Disorders: Risk, Classification, and Therapeutic Recommendations | Current Treatment Options in Oncology | 2012 | 145 |
| 15 | Primary thyroid lymphomas | Current Treatment Options in Oncology | 2004 | 139 |
| 16 | Treatment of Relapsed Acute Myeloid Leukemia | Current Treatment Options in Oncology | 2020 | 138 |
| 17 | Targeted Therapies in Advanced Gastric Cancer | Current Treatment Options in Oncology | 2020 | 133 |
| 18 | Solitary bone plasmacytoma and extramedullary plasmacytoma | Current Treatment Options in Oncology | 2002 | 132 |
| 19 | Managing the cognitive effects of brain tumor radiation therapy | Current Treatment Options in Oncology | 2006 | 132 |
| 20 | Ewing’s Sarcoma: Standard and Experimental Treatment Options | Current Treatment Options in Oncology | 2009 | 127 |
| 21 | The Clinical Management of Chondrosarcoma | Current Treatment Options in Oncology | 2009 | 120 |
| 22 | The Multidisciplinary Management of Osteosarcoma | Current Treatment Options in Oncology | 2009 | 118 |
| 23 | Role of Anti-angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors | Current Treatment Options in Oncology | 2007 | 115 |
| 24 | Exercise in Prevention and Management of Cancer | Current Treatment Options in Oncology | 2008 | 115 |
| 25 | Cardiac Tumors: Clinical Presentation, Diagnosis, and Management | Current Treatment Options in Oncology | 2019 | 115 |
| 26 | Imaging in head and neck cancer | Current Treatment Options in Oncology | 2006 | 112 |
| 27 | Treatment of NRAS-Mutant Melanoma | Current Treatment Options in Oncology | 2015 | 110 |
| 28 | Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment | Current Treatment Options in Oncology | 2018 | 108 |
| 29 | Parathyroid carcinoma | Current Treatment Options in Oncology | 2001 | 106 |
| 30 | Malignant gliomas | Current Treatment Options in Oncology | 2000 | 104 |
| 31 | Oral cancer treatment | Current Treatment Options in Oncology | 2003 | 100 |
| 32 | Epidemiology of Head and Neck Squamous Cell Carcinomas: Impact on Staging and Prevention Strategies | Current Treatment Options in Oncology | 2019 | 99 |
| 33 | Nonmelanoma skin cancer | Current Treatment Options in Oncology | 2002 | 98 |
| 34 | Bone Tumors in Adolescents and Young Adults | Current Treatment Options in Oncology | 2008 | 96 |
| 35 | Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis | Current Treatment Options in Oncology | 2016 | 96 |
| 36 | Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future | Current Treatment Options in Oncology | 2016 | 95 |
| 37 | Cancer Cachexia: Traditional Therapies and Novel Molecular Mechanism-Based Approaches to Treatment | Current Treatment Options in Oncology | 2010 | 94 |
| 38 | Radiation-induced sarcoma | Current Treatment Options in Oncology | 2000 | 92 |
| 39 | Update on PARP Inhibitors in Breast Cancer | Current Treatment Options in Oncology | 2018 | 92 |
| 40 | Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence | Current Treatment Options in Oncology | 2018 | 92 |
| 41 | Metastatic melanoma | Current Treatment Options in Oncology | 2001 | 91 |
| 42 | Papillary thyroid cancer: Surgical management of lymph node metastases | Current Treatment Options in Oncology | 2005 | 91 |
| 43 | Circulating Tumor Cells in Colorectal Cancer: Past, Present, and Future Challenges | Current Treatment Options in Oncology | 2010 | 91 |
| 44 | Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice | Current Treatment Options in Oncology | 2016 | 88 |
| 45 | Merkel Cell Carcinoma Therapeutic Update | Current Treatment Options in Oncology | 2016 | 88 |
| 46 | Chinese Herbal Medicines in the Treatment of IBD and Colorectal Cancer: A Review | Current Treatment Options in Oncology | 2014 | 87 |
| 47 | Chemotherapy-Resistant Metastatic Breast Cancer | Current Treatment Options in Oncology | 2012 | 86 |
| 48 | Metastatic colorectal cancer | Current Treatment Options in Oncology | 2001 | 85 |
| 49 | Management of pineal region tumors | Current Treatment Options in Oncology | 2006 | 85 |
| 50 | Neuroendocrine Pancreatic Tumors: Guidelines for Management and Update | Current Treatment Options in Oncology | 2012 | 85 |
